Loading
A phase 2 trial of (Z)-endoxifen in HR-positive / HER2-negative breast cancer, run by Atossa Therapeutics, Inc., active and no longer recruiting.
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer is a phase 2 interventional study registered as NCT05607004 by Atossa Therapeutics, Inc., with 87 participants enrolled, started 2023-02-14 and due to reach its primary completion in 2026-11. Interventions recorded: (Z)-endoxifen and goserelin.
Shares High-risk early HR-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares High-risk early HR-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares High-risk early HR-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HR-positive / HER2-negative breast cancer and the tag pipeline.